The PACAP receptor: a novel target for migraine treatment.
The origin of migraine pain has not yet been clarified, but accumulating data point to neuropeptides present in the perivascular space of cranial vessels as important mediators of nociceptive input during migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is present in sensory trigeminal neurons and may modulate nociception at different levels of the nervous system. Human experimental studies have shown that PACAP-38 infusion induces marked dilatation of extracerebral vessels and delayed migraine-like attacks in migraine patients. PACAP selectively activates the PAC(1) receptor, which suggests a possible signaling pathway implicated in migraine pain. This review summarizes the current evidence supporting the involvement of PACAP in migraine pathophysiology and the PAC(1) receptor as a possible novel target for migraine treatment.
Schytz
Henrik W
HW
Danish Headache Center and Department of Neurology, Glostrup Hospital, Faculty Of Health Sciences, University of Copenhagen, 2600 Glostrup, Denmark.
Olesen
Jes
J
Ashina
Messoud
M
D000818:Animals; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008881:Migraine Disorders / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism*; D008954:Models, Biological; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D051236:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide / Q000378:metabolism*; D014665:Vasodilator Agents / Q000009:adverse effects
D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D051236:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide; D014665:Vasodilator Agents